United Therapeutics Ovarian Cancer Drug Closer to Commercialization
(PRLEAP.COM) SARASOTA, Fla., March 14, 2006 (PR Leap)—Dr. Lorne Tyrrell, Chief Executive of ViRexx Medical (AMEX: REX; Toronto: VIR), told StockInterview, “This is a study where the drug has been given fast track approval and orphan drug status.” Dr. Tyrrell referred to the Phase III clinical trials now being conducted for his company’s monoclonal antibody OvaRex MAb. A subsidiary of United Therapeutics (NASDAQ: UTHR), which has licensed OvaRex from ViRexx Medical is testing the ovarian cancer drug on more than 300 late-stage ovarian cancer patients in more than 60 research centers across the U.S.
According to Dr. Tyrrell, OvaRex had been tested in Canada prior to the current testing, “There have been a number of patients that have received OvaRex. We’ve had no adverse effects from these patients.” Dr. Tyrrell is on sabbatical from the University of Alberta, as professor or medical microbiology and immunology, to ensure OvaRex MAb continues advancing through the current clinical studies and into the marketplace.
Will OvaRex MAb cure ovarian cancer? Dr. Tyrrell told StockInterview, “In most cases, it will be a delay (of death). We hope that one day we will be able to cure this disease. This has the potential to be an important step at helping to stimulate immune response to achieve a better outcome. Hopefully, one day we can improve that to where it is a cure.” Said Chief Executive of United Therapeutics Martine Rothblatt, “It is our hope that OvaRex will help women and their physicians combat this disease.”
Market Outlook Journal
Dr. Tyrrell is featured in StockInterview’s Market Outlook Journal, which can be viewed in its entirety at http://www.stockinterview.com/journal.html
About ViRexx Medical
ViRexx Medical Corp. (AMEX: REX; Toronto: VIR) is a biotechnology company, which develops therapeutic products for the treatment of chronic Hepatitis B, Hepatitis C, other infectious diseases, and selected solid tumors. The company’s lead product OvaRex MAb is currently undergoing Phase III clinical trials through a subsidiary of United Therapeutics.
CONTACT:
Julie Ickes,
Editor, StockInterview.com
Tel: 1-941-929-1640
Email: editor@stockinterview.com
WWW: http://www.stockinterview.com
(SOURCE: StockInterview.com)
Contact Information
About This News Release
If you have any questions regarding information in these press releases please contact the organization listed in the press release. Issuers of press releases and not PR Leap are solely responsible for the accuracy of the content.
Your News Online
Over 30,000 companies use PR LEAP
PR LEAP offers an SEO and Social Media press release distribution service that is more affordable than the top 3 wires. Our member's press releases can be found on Google News, Google Search, Yahoo!, MSN, Ask.com News, Ask.com, Topix.net and many more.
Pricing & Signup